ESMO 2025 brought together the brightest minds in oncology to explore the future of cancer care. With so much data and discussion, our HRW OR:BIT team focused on boiling it down to the fundamental questions shaping the field. In this blog, we explore the Who, What, Where, When, Why, and How of oncology innovation, offering actionable insights for pharma and healthcare insight managers looking to stay ahead. Who truly benefits from earlier intervention? Not all early treatments lead to better outcomes. Trials like ENZARD, EMBARK, PRESTO, and POTOMAC revealed that timing and disease biology are critical. In indolent cancers, early aggressive therapy may cause unnecessary toxicity without improving survival. The takeaway? Biomarker-driven approaches are essential to identify which patients will truly benefit from early treatment, helping avoid overtreatment and improve outcomes. What novel mechanisms are reshaping cancer therapy? This year’s ESMO spotlighted innovative molecular targets and immune-modulating therapies: -DLL3-directed T-cell engagers (DeLLphi-303, ZG006) showed survival benefits across tumor types. -Bispecific antibodies like PD-1/TIGIT combinations (ZG005, Rilvegostomig) are gaining traction. -ADCs such as Iza-Bren targeting EGFR/HER3 mutations showed strong response rates in NSCLC and head & neck cancers. -Clever-1 antibodies reprogram macrophages in high-risk MDS. -Dual PD-1/VEGF blockade in the HARMONi-6 trial showed promising results. These mechanisms are paving the way for more precise and effective cancer treatments. Where does the opportunity lie to truly impact patients? Beyond efficacy, patient-centered care is becoming a priority. ESMO 2025 emphasized the importance of supporting patients holistically, from diagnosis through survivorship.Pharma brands have an opportunity to lead with purpose by offering support beyond the pill. This means understanding the emotional experience of patients and fostering empathetic, inclusive care. When will clinical trials reflect true equity? Global equity in trial design remains a challenge. Region-specific trials like HARMONi-6 and OptiTROP-Lung04 highlight the need for cross-border collaboration and harmonized protocols. Underrepresentation of Black/African patients in trials. especially in breast and prostate cancers, continues to be a concern. To drive change, trials must be inclusive by design, with diverse leadership, decentralized models, and community engagement. Why are earlier endpoints essential? Crossover in trials, where control patients switch to experimental therapies, can blur survival outcomes. Waiting for overall survival (OS) maturity delays access to life-changing treatments. There’s a growing push for earlier surrogate endpoints that preserve trial integrity and accelerate access. These endpoints must be validated by tumor type, and AI-powered data mining may help achieve this. How can we design better trials? As therapies become more robust, trial designs must evolve. There’s a call to isolate the impact of neoadjuvant vs. adjuvant phases and explore de-escalation strategies. Adaptive trial designs that adjust dosing based on early response indicators support the “less is more” approach, preserving efficacy while minimizing toxicity. How can brands differentiate in crowded landscapes? With many therapies targeting similar pathways, strategic positioning and patient-centricity are key. Brands must: -Focus on high unmet-need populations -Help HCPs identify the right patients -Move away from “all-comers” messaging -Create distinct patient personas Precision matters. Brands that clarify who benefits most will stand out in competitive markets. By Sidak Seth and Marianne Ibrahim Want to explore how these insights could shape your brand strategy in oncology? Fill out the contact us form below, or reach out to the team directly at HRW-ORBIT@hrwhealthcare.com Apply Now!